Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy - PubMed
2 hours ago
- #intestinal barrier
- #chemotherapy side-effects
- #gut microbiome
- Rifaximin reduces intestinal mucositis from chemotherapy without affecting anti-tumor efficacy.
- Microbiome changes with rifaximin involve Muribaculum, which alone mimics protection.
- Human ex-vivo studies confirm rifaximin’s role in preserving mucosal and barrier integrity.